Abstract:The delivery of radiation therapy (RT) for cancer with intent to cure has been optimized and standardized over the last 80 years. Both preclinical and clinical work emphasized the observation that radiation destroys the tumor and exposes its components to the immune response in a mode that facilitates the induction of anti-tumor immunity or reinforces such a response. External beam photon radiation is the most prevalent in situ abolition treatment, and its use exposed the “abscopal effect”. Particle radiotherapy (PRT), which has been in various stages of research and development for 70 years, is today available for the treatment of patients in the form of alpha particles, proton, or carbon ion radiotherapy. Charged particle radiotherapy is based on the acceleration of charged species, such as protons or carbon-12, which deposit their energy in the treated tumor and have a higher relative biological effectiveness compared with photon radiation. In this review, we will bring evidence that alpha particles, proton, or carbon ion radiation can destroy tumors and activate specific anti-tumor immune responses. Radiation may also directly affect the distribution and function of immune cells such as T cells, regulatory T cells, and mononuclear phagocytes. Tumor abolition by radiation can trigger an immune response against the tumor. However, abolition alone rarely induces effective anti-tumor immunity resulting in systemic tumor rejection. Immunotherapy can complement abolition to reinforce the anti-tumor immunity to better eradicate residual local and metastatic tumor cells. Various methods and agents such as immunoadjuvants, suppressor cell inhibitors, or checkpoint inhibitors were used to manipulate the immune response in combination with radiation. This review deals with the manifestations of particle-mediated radiotherapy and its correlation with immunotherapy of cancer.

Radiopharmaceuticals Heat Anti-Tumor Immunity

The role of radiotherapy in tumor immunity and the potential of PET/CT in detecting the expression of PD-1/PD-L1

Immunological effects of radiopharmaceutical therapy

Research Progress on the Mechanism of Anti-Tumor Immune Response Induced by TTFields

Positron Emission Tomography Molecular Imaging to Monitor Anti-Tumor Systemic Response for Immune Checkpoint Inhibitor Therapy

Peptide-based Radiopharmaceuticals for Targeted Tumor Therapy

Treating Deep-Seated Tumors with Radio-Dynamic Therapy: Progress and Perspectives

Radioligand Therapy in Lymphoma: Past, Present, and Future

Treating Deep-Seated Tumors with Radiodynamic Therapy: Progress and Perspectives

Optimizing Radioimmunoconjugate Delivery in the Treatment of Solid Tumor

Irradiated tumor cell-derived microparticles mediate tumor eradication via cell killing and immune reprogramming

Intranuclear Irradiation Inhibits Solid Tumor Growth by Upregulating Caspase8 and Activating Apoptosis

Radiotherapy-Mediated Immunomodulation and Anti-Tumor Abscopal Effect Combining Immune Checkpoint Blockade

Immune targets in the tumor microenvironment treated by radiotherapy

Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy

Rhythm Mild-Temperature Photothermal Therapy Enhancing Immunogenic Cell Death Response in Oral Squamous Cell Carcinoma

Radiation-induced Tumor Immune Microenvironments and Potential Targets for Combination Therapy

Radiotherapy combined with immunotherapy: the dawn of cancer treatment

Induction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with 177Lu-Dotatate in a Murine Model of a Human Neuroendocrine Tumor

The Potentiation of Anti-Tumor Immunity by Tumor Abolition with Alpha Particles, Protons, or Carbon Ion Radiation and Its Enforcement by Combination with Immunoadjuvants or Inhibitors of Immune Suppressor Cells and Checkpoint Molecules

Pretargeted radioimmunotherapy with the novel anti-oxMIF/HSG bispecific antibody ON105 results in significant tumor regression in murine models of cancer